Published in Clin Chem on July 01, 2003
Human cannabinoid pharmacokinetics. Chem Biodivers (2007) 1.91
Excretion of Delta9-tetrahydrocannabinol in sweat. Forensic Sci Int (2007) 0.98
Practical challenges to positive drug tests for marijuana. Clin Chem (2003) 0.83
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Identifying health disparities across the tobacco continuum. Addiction (2007) 3.40
Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend (2003) 2.68
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Cannabis effects on driving skills. Clin Chem (2012) 2.04
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures. Exp Clin Psychopharmacol (2007) 1.94
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Guidelines for research on drugged driving. Addiction (2008) 1.87
Methadone maintenance and breastfeeding in the neonatal period. Pediatrics (2008) 1.86
Smoking topography: reliability and validity in dependent smokers. Nicotine Tob Res (2003) 1.83
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem (2003) 1.66
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol (2005) 1.65
Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry (2012) 1.62
Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray. Neuropsychopharmacology (2007) 1.56
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A (2010) 1.53
Differences in risk-taking propensity across inner-city adolescent ever- and never-smokers. Nicotine Tob Res (2005) 1.50
National patterns and correlates of mentholated cigarette use in the United States. Addiction (2010) 1.41
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend (2009) 1.40
Youth tobacco use: a global perspective for child health care clinicians. Pediatrics (2006) 1.35
A quantitative analysis of subjective, cognitive, and physiological manifestations of the acute tobacco abstinence syndrome. Addict Behav (2010) 1.32
Nicotine dependence and quitting behaviors among menthol and non-menthol smokers with similar consumptive patterns. Addiction (2010) 1.32
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom (2003) 1.31
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/hyperactivity disorder. Pediatrics (2006) 1.29
A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res (2003) 1.28
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature. J Forensic Sci (2013) 1.26
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics (2010) 1.26
Cognitive measures in long-term cannabis users. J Clin Pharmacol (2002) 1.23
Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem (2002) 1.23
Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev (2006) 1.22
Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol (2010) 1.22
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr (2010) 1.21
Tobacco Craving Questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res (2003) 1.21
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (2009) 1.21
Prenatal and postnatal cocaine exposure predict teen cocaine use. Neurotoxicol Teratol (2010) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Shorter time to first cigarette of the day in menthol adolescent cigarette smokers. Addict Behav (2005) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit (2004) 1.16
Clove cigarette smoking: biochemical, physiological, and subjective effects. Pharmacol Biochem Behav (2003) 1.16
Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol (2009) 1.16
Oral fluid as a diagnostic tool. Clin Chem Lab Med (2004) 1.15
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 1.15
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend (2012) 1.14
Associations between Cloninger's temperament dimensions and acute tobacco withdrawal. Addict Behav (2007) 1.13
Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact (2007) 1.12
Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol (2010) 1.11
Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol (2003) 1.11
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend (2008) 1.11
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol (2008) 1.10
Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit (2009) 1.10
Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol (2009) 1.09
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Tobacco craving predicts lapse to smoking among adolescent smokers in cessation treatment. Nicotine Tob Res (2007) 1.09
Cannabinoid concentrations in hair from documented cannabis users. Forensic Sci Int (2006) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit (2006) 1.07
A mechanism for the inhibition of neural progenitor cell proliferation by cocaine. PLoS Med (2008) 1.07
Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem (2009) 1.05
A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem (2009) 1.05
Metabolic effects of chronic cannabis smoking. Diabetes Care (2013) 1.04
Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J Med Chem (2008) 1.04
The state of office-based interventions for youth tobacco use. Pediatrics (2003) 1.04
A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Mass Spectrom (2006) 1.04
Sex-based and hormonal contraception effects on the metabolism of nicotine among adolescent tobacco-dependent smokers. Nicotine Tob Res (2007) 1.04
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.03
Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study. Cereb Cortex (2008) 1.03
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.03
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics (2012) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
Tobacco smoking trajectory and associated ethnic differences among adolescent smokers seeking cessation treatment. J Adolesc Health (2004) 1.02
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem (2013) 1.01
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J (2006) 1.01
Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. Nicotine Tob Res (2010) 1.01
Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem (2013) 1.01
Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration. Clin Chem (2005) 1.01
Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration. J Anal Toxicol (2006) 1.01